DOCSLIB.ORG

Gastroenterology General Referral Guidelines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gastroenterology General Referral Guidelines Page | 1 Gastroenterology General Referral Guidelines Department of Health clinical urgency categories for specialist clinics Urgent: A referral is urgent if the patient has a condition that has major functional impairment and/or moderate risk of permanent damage to an organ/bone/tissue/system if not seen within 30 days. Semi Urgent: Referrals should be categorised as Semi Urgent where the patient has a condition that has the potential to deteriorate within 30-90 days. Routine: Referrals should be categorised as routine if the patient’s condition is unlikely to deteriorate quickly or have significant consequences for the person’s health and quality of life if specialist assessment is delayed beyond one month. Exclusions: The following conditions should not be referred to outpatients, but rather patients should be advise to present directly to A&E: ‘Active haematemesis and/or melaena; Acute severe colitis; Jaundice with fever / abdominal pain, Food bolus obstruction, Suspected bowel obstruction Decompensated cirrhosis with encephalopathy, jaundice or sepsis; Clinically significant ascites/hepatic hydrothorax’. Patients with Hepatocellular Carcinoma should not be referred to outpatients or present to A&E, rather referred directly to the Hepatocellular Carcinoma Unit. See Referral Form and Referral Guidelines. These guidelines have been set by DHHS: src.health.vic.gov.au Condition / Symptom Criteria for Referral Information to be included Expected Triage Outcome Austin Specific Guidance Notes Abnormal liver function 1. Features suggestive of Must be provided: Urgent if aspartate tests cirrhosis: 1. History of alcohol intake transaminase (AST) or platelet count < 120 x 109 2. History of injectable drug use alanine aminotransferase Direct to Emergency Department for: per litre 3. Current and historical liver function (ALT) ≥ 5 times the upper Acute liver failure splenomegaly tests level of the normal range Severe hepatic ascites 4. Full blood examination encephalopathy hepatic encephalopathy 5. International normalised ration (INR) Routine otherwise Aspartate transaminase result (AST) > 2,000 U/L. 2. Genetic haemochromatosis 6. Urea and electrolytes (C282Y homozygotes and 7. Upper abdominal ultrasound results C282Y/H63D compound 8. Hepatitis B virus and Hepatitis C virus heterozygotes only) serology results 3. Abnormal liver function test 9. History of diabetes with aspartate transaminase 10. Iron studies (AST) or alanine 11. Current and complete medication aminotransferase (ALT) ≥ 5 history (including non-prescription times the upper level of the medicines, herbs and supplements). normal range Provide if available: 1. Height, weight and body mass index 1. Two abnormal liver function 2. Any relevant family history. test results performed at least 3 months apart with aspartate Austin Health Template Referral Guidelines | Created: 21/01/2020 By: Dr Josephine Grace. Last Reviewed: Dr Josephine Grace 24/01/2020. Review & Update By: 23/01/2022. Page | 2 These guidelines have been set by DHHS: src.health.vic.gov.au Condition / Symptom Criteria for Referral Information to be included Expected Triage Outcome Austin Specific Guidance Notes transaminase (AST) or alanine aminotransferase (ALT) 2-5 times the upper level of the normal range. Referral not appropriate for: 1. Fatty liver with normal liver function tests. Chronic refractory Must be provided: Routine constipation 1. Constipation lasting more 1. Onset, characteristics and duration of Direct to Emergency Department for: than 12 months with refractory symptoms that affect the symptoms Suspected large bowel 2. Details of previous medical obstruction person’s activities of daily living despite an adequate management including the course of Faecal impaction that has trial of treatment. treatment and outcome of treatment not responded to adequate 3. Current and complete medication medical management. history (including non-prescription Referral not appropriate for: medicines, herbs and supplements) 1. Patients with no sentinel 4. Thyroid stimulating hormone levels findings, who have not had an 5. Serum calcium. adequate trial of treatment (e.g. regular osmotic laxatives) Provide if available: Additional comments: 2. Laxative dependence. 1. Current and previous colonoscopy 1. The referral should note that the results request is for advice on, or 2. Details of any previous gastroenterology review of, the current assessments or opinions. management plan as requests 3. Current and previous imaging results. for a second opinion will usually not be accepted. 2. See also: statewide referral criteria for Constipation with Sentinel Findings Chronic refractory Routine diarrhoea 1. Chronic refractory diarrhoea Must be provided: 1. Onset, characteristics and duration of lasting more than 6 months with refractory symptoms symptoms Additional Comments: 2. Details of previous medical 1. The referral should note that the (following an adequate trial of treatment) that affect the management including the course of request is for advice on, or treatment and outcome of treatment review of, the current Austin Health Template Referral Guidelines | Created: 21/01/2020 By: Dr Josephine Grace. Last Reviewed: Dr Josephine Grace 24/01/2020. Review & Update By: 23/01/2022. Page | 3 These guidelines have been set by DHHS: src.health.vic.gov.au Condition / Symptom Criteria for Referral Information to be included Expected Triage Outcome Austin Specific Guidance Notes management plan as requests person’s activities of daily 3. Details of any previous gastroenterology for a second opinion will usually living. assessments or opinions not be accepted. 4. Previous histopathology results. 2. See also: statewide referral criteria for Diarrhoea with Provide if available: sentinel findings 1. Full blood examination 2. Iron studies Referral not appropriate for: 3. Vitamin B12 and folate test results 1. Laxative dependence. 4. 25-OH vitamin D results 5. Faecal calprotectin 6. Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) 7. Previous colonoscopy results. Cirrhosis Must be provided: Urgent if hepatic Direct to Emergency Department for: 1. Suspected cirrhosis encephalopathy, ascites or suggested by one or more of 1. History of alcohol intake jaundice Acute liver failure the following: 2. History of injectable drug use < 3 months otherwise Sepsis in a patient with evidence of cirrhosis on 3. Current and historical liver function cirrhosis imaging tests Severe hepatic platelet count < 120 x 109 4. Full blood examination encephalopathy per litre 5. International normalised ration (INR) Severe ascites restricting ascites result movement and breathing. hepatic encephalopathy 6. Urea and electrolytes AST to platelet ratio index 7. Upper abdominal ultrasound results (APRI) >2.0. 8. Hepatitis B virus and Hepatitis C virus serology results 9. History of diabetes 10. Iron studies 11. Current and complete medication history (including non-prescription medicines, herbs and supplements). Provide if available: 1. Height, weight and body mass index. Coeliac disease Must be provided: <3 months GP Management: 1. Positive coeliac serology If coeliac disease 2. Advice on, or review of, 1. Coeliac serology results or previous confirmed (positive symptomatic coeliac disease histology results serology and abnormal Austin Health Template Referral Guidelines | Created: 21/01/2020 By: Dr Josephine Grace. Last Reviewed: Dr Josephine Grace 24/01/2020. Review & Update By: 23/01/2022. Page | 4 These guidelines have been set by DHHS: src.health.vic.gov.au Condition / Symptom Criteria for Referral Information to be included Expected Triage Outcome Austin Specific Guidance Notes (previous histological 2. Full blood examination small bowel biopsy), refer diagnosis) not responding to 3. Iron studies. to a dietitian for gluten- dietary and medical free diet. management. Provide if available: 1. Gastrointestinal symptoms (e.g. If diagnostic uncertainty Referral not appropriate for: diarrhoea, weight loss) await specialist clinic 1. Positive coeliac gene test 2. Previous gastroscopy results appointment before without positive coeliac 3. Previous histology results commencing gluten free serology. 4. Previous gastroenterology assessments diet. or opinions 5. Urea and electrolytes 6. Liver function tests 7. Details of previous medical management including the course of treatment and outcome of treatment 8. Details of any other autoimmune conditions. Constipation with sentinel 1. Constipation in patients with Must be provided: Patients with positive findings a duration of more than 6 1. Onset, characteristics and duration of Urgent faecal occult blood test weeks but less than 12 constipation and sentinel findings may be triaged to Direct to Emergency Department for: months, with any of the 2. Current and previous colonoscopy colonoscopy prior to the following: results appointment at a Suspected large bowel >40 years of age 3. Full blood examination specialist clinic. obstruction rectal bleeding 4. Iron studies Faecal impaction that has positive faecal occult not responded to adequate blood test Provide if available medical management. weight loss (≥ 5% of body 1. Current and previous histology results weight in previous 6 2. Details of any previous gastroenterology months) assessments or opinions 3. Faecal occult blood test abdominal or rectal mass Additional Comments: 4. Thyroid stimulating hormone levels iron deficiency that 1. As part of the referral persists despite assessment, patients may be triaged by phone direct
Load more

Recommended publications
  • Atypical Abdominal Pain in a Patient with Liver Cirrhosis
    IMAGE IN HEPATOLOGY January-February, Vol. 17 No. 1, 2018: 162-164 The Official Journal of the Mexican Association of Hepatology, the Latin-American Association for Study of the Liver and the Canadian Association for the Study of the Liver Atypical Abdominal Pain in a Patient With Liver Cirrhosis Liz Toapanta-Yanchapaxi,* Eid-Lidt Guering,** Ignacio García-Juárez* * Gastroenterology Department. National Institute of Medical Science and Nutrition “Salvador Zubirán”. Mexico City. Mexico. ** Interventional Cardiology. National Institute of Cardiology “Ignacio Chávez”. Mexico City. Mexico. ABSTRACTABSTABSTABSTRACT The causes of abdominal pain in patients with liver cirrhosis and ascites are well-known but occasionally, atypical causes arise. We report the case of a patient with a ruptured, confined abdominal aortic aneurysm. KeyK words.o d .K .Key Liver cirrhosis. Abdominal aortic aneurysm. INTRODUCTION CASE REPORT Abdominal pain in cirrhotic patients is a challenge. A 47-year-old male with the established diagnosis of Clinical presentation can be non-specific and the need for alcohol-related liver cirrhosis, presented to the emer- early surgical exploration may be difficult to assess. Coag- gency department for abdominal pain. He was classified ulopathy, thrombocytopenia, varices, and ascites need to as Child Pugh (CP) C stage (10 points) and had a model be taken into account, since they can increase the surgical for end stage liver disease (MELD) - sodium (Na) of 21 risk. Possible differential diagnoses include: Complicated points. The pain was referred to the left iliac fossa, with umbilical, inguinal or postoperative incisional hernias, an intensity of 10/10. It was associated to low back pain acute cholecystitis, spontaneous bacterial peritonitis, pep- with radicular stigmata (primarily S1).
    [Show full text]
  • High Risk Percutaneous Endoscopic Gastrostomy Tubes: Issues to Consider
    NUTRITIONINFLAMMATORY ISSUES BOWEL IN GASTROENTEROLOGY, DISEASE: A PRACTICAL SERIES APPROACH, #105 SERIES #73 Carol Rees Parrish, M.S., R.D., Series Editor High Risk Percutaneous Endoscopic Gastrostomy Tubes: Issues to Consider Iris Vance Neeral Shah Percutaneous endoscopy gastrostomy (PEG) tubes are a valuable tool for providing long- term enteral nutrition or gastric decompression; certain circumstances that complicate PEG placement warrant novel approaches and merit review and discussion. Ascites and portal hypertension with varices have been associated with poorer outcomes. Bleeding is one of the most common serious complications affecting approximately 2.5% of all procedures. This article will review what evidence exists in these high risk scenarios and attempt to provide more clarity when considering these challenging clinical circumstances. INTRODUCTION ince the first Percutaneous Endoscopic has been found by multiple authors to portend a poor Gastrostomy tube was placed in 1979 (1), they prognosis in PEG placement (3,4, 5,6,7,8). This review Shave become an invaluable tool for providing will endeavor to provide more clarity when considering long-term enteral nutrition (EN) and are commonly used these challenging clinical circumstances. in patients with dysphagia following stroke, disabling motor neuron diseases such as multiple sclerosis and Ascites & Gastric Varices amyotrophic lateral sclerosis, and in those with head The presence of ascites is frequently viewed as a and neck cancer.They are also used for patients with relative, if not absolute, contraindication to PEG prolonged mechanical intubation, as well as gastric placement. Ascites adds technical difficulties and the decompression in those with severe gastroparesis, risk for potential complications (see Table 1).
    [Show full text]
  • Septicaemia After Colonoscopy in Patients With
    450 Gut, 1991,32,450-451 Septicaemia after colonoscopy in patients with cirrhosis Gut: first published as 10.1136/gut.32.4.450 on 1 April 1991. Downloaded from j R Thornton, M S Losowsky Abstract PATIENT 2 Two patients with ulcerative colitis and In 1987, a 34 year old man underwent routine chronic active hepatitis with cirrhosis, who colonoscopy because ofhis ulcerative colitis of 12 developed Gram negative septicaemia after years' duration. Twenty three years earlier a colonoscopy are described. These and two liver biopsy had shown that he had chronic similar reported cases indicate that giving active hepatitis and cirrhosis. Hepatitis B prophylactic antibiotics to patients with cir- markers were negative. In 1983 he developed rhosis undergoing colonoscopy should be con- ascites and had remained on spironolactone since sidered, particularly when the cirrhosis is then. advanced. At the time ofhis colonoscopy he claimed that he felt reasonably well and was continuing to work. However, he had a moderate amount of Prophylactic antibiotics have been advised for ascites. His medication was: prednisolone 5 mg patients undergoing colonoscopy who have daily, spironolactone 200 mg daily, and sul- valvular heart disease, cardiac prostheses, severe phasalazine 1 g twice daily. Preoperative blood immunodepression, or hepatic cirrhosis with tests were: bilirubin 53 ,umol/1, alanine amino- ascites.' The last of these recommendations is transferase 38 IU/, alkaline phosphatase 206 IU/ based on a single case report in which it was not 1, albumin 28 g/l, prothrombin time 16 seconds certain that colonoscopy was responsible for the (control 14 seconds). infection, as hepatic angiography was performed After bowel preparation with three litres of the day before peritonitis developed.' We were Golytely, colonoscopy to the caecum was per- unaware of this case but our recent experience formed.
    [Show full text]
  • Ultra-Sound Guided Liver Biopsy
    Ultra-Sound Guided Liver Biopsy What is a liver biopsy? A liver biopsy is a procedure used for making the diagnosis of abnormal liver conditions. A small piece of liver tissue is removed using a special needle for examination under a microscope. The liver tissue allows the doctor to see if your liver is healthy or to better understand why you have liver damage or disease and how severe any damage is. The most common method of liver biopsy is percutaneously (“through the skin”). This procedure is often performed as an outpatient and does not routinely require hospital admission. A qualified gastroenterologist does the liver biopsy. This is a doctor who specializes in diseases of the digestive system and liver. Does the liver biopsy hurt? You may feel minor discomfort during the biopsy. Some people do have some discomfort at the site of the biopsy for the first 24 to 48 hours after the procedure but this is often relieved by simple painkillers such as Tylenol. Why do I need a liver biopsy? Your doctor will have discussed this with you or written to you about the need for a liver biopsy. If you have any questions, please ask. This test may be carried out for a number of reasons. Common indications include: Your symptoms, blood tests and scans (ultrasound, CT or MRI scans) suggest you have liver disease. However, sometimes it is not possible to tell what the cause is on the basis of these tests alone. There appears to be a lump in your liver which has been seen on previous scans and a sample of tissue is needed to identify what it is.
    [Show full text]
  • AASLD Position Paper : Liver Biopsy
    AASLD POSITION PAPER Liver Biopsy Don C. Rockey,1 Stephen H. Caldwell,2 Zachary D. Goodman,3 Rendon C. Nelson,4 and Alastair D. Smith5 This position paper has been approved by the AASLD and College of Cardiology and the American Heart Associa- represents the position of the association. tion Practice Guidelines3).4 Introduction Preamble Histological assessment of the liver, and thus, liver bi- These recommendations provide a data-supported ap- opsy, is a cornerstone in the evaluation and management proach. They are based on the following: (1) formal re- of patients with liver disease and has long been considered view and analysis of the recently published world to be an integral component of the clinician’s diagnostic literature on the topic; (2) American College of Physi- armamentarium. Although sensitive and relatively accu- cians Manual for Assessing Health Practices and De- rate blood tests used to detect and diagnose liver disease signing Practice Guidelines1; (3) guideline policies, have now become widely available, it is likely that liver including the AASLD Policy on the Development and biopsy will remain a valuable diagnostic tool. Although Use of Practice Guidelines and the American Gastro- histological evaluation of the liver has become important enterological Association Policy Statement on Guide- in assessing prognosis and in tailoring treatment, nonin- lines2; and (4) the experience of the authors in the vasive techniques (i.e., imaging, blood tests) may replace specified topic. use of liver histology in this setting, particularly with re- Intended for use by physicians, these recommenda- gard to assessment of the severity of liver fibrosis.5,6 Sev- tions suggest preferred approaches to the diagnostic, ther- eral techniques may be used to obtain liver tissue; a table apeutic, and preventive aspects of care.
    [Show full text]
  • Detailed Categories 2016-Update
    KNHSS Kuwait National Healthcare-associated Infections Surveillance System 5. Bile duct, liver or pancreatic surgery Excision of bile ducts or operative procedures on the biliary tract, liver or pancreas (does not include operations only on gallbladder) 50.0 Hepatotomy Incision of abscess of liver Removal of gallstones from liver Stromeyer-Little operation 50.12 Open biopsy of liver Wedge biopsy 50.14 Laparoscopic liver biopsy Excludes: Closed (percutaneous)[needle] biopsy of liver (50.11) Transjugular liver biopsy (50.13) 50.21 Marsupialization of lesion of liver 50.22 Partial hepatectomy Wedge resection of liver Excludes: Closed (percutaneous)[needle] biopsy of liver (50.11) 50.23 Open ablation of liver lesion or tissue 50.25 Laparoscopic ablation of liver lesion or tissue 50.26 Other and unspecified ablation of liver lesion or tissue 50.29 Other destruction of lesion of liver Cauterization of hepatic lesion Enucleation of hepatic lesion Evacuation of hepatic lesion Excludes: Percutaneous ablation of liver lesion or tissue (50.24) Percutaneous aspiration of lesion (50.91) Laser interstitial thermal therapy [LITT] of lesion or tissue of liver under guidance(17.63) 1 KNHSS Kuwait National Healthcare-associated Infections Surveillance System 50.3 Lobectomy of liver 50.4 Total hepatectomy 50.61 Closure of laceration of liver 50.69 Other repair of liver Hepatopexy 51.31 Anastomosis of gallbladder to hepatic ducts 51.32 Anastomosis of gallbladder to intestine 51.33 Anastomosis of gallbladder to pancreas 51.34 Anastomosis of
    [Show full text]
  • Liver Biopsy
    William F. Erber, M.D., P.C. Gastroenterology and Endoscopy Diseases of the Digestive Tract, Liver and Pancreas Board Certified William F. Erber, M.D., F.A.C.P., F.A.C.G., A.G.A.F. 591 Ocean Parkway Jonathan A. Erber, M.D. Brooklyn, N.Y. 11218 Tel (718) 972-8500 Fax (718) 972-0064 www.drerber.com Liver Biopsy In a liver biopsy (BYE-op-see), the physician examines a small piece of tissue from your liver for signs of damage or disease. A special needle is used to remove the tissue from the liver. The physician decides to do a liver biopsy after tests suggest that the liver does not work properly. For example, a blood test might show that your blood contains higher than normal levels of liver enzymes or too much iron or copper. An x ray could suggest that the liver is swollen. Looking at liver tissue itself is the best way to determine whether the liver is healthy or what is causing it to be damaged. Preparation Before scheduling your biopsy, the physician will take blood samples to make sure your blood clots properly. Be sure to mention any medications you take, especially those that affect blood clotting, like blood thinners. One week before the procedure, you will have to stop taking aspirin, ibuprofen, and anticoagulants. The digestive system You must not eat or drink anything for 8 hours before the biopsy, and you should plan to arrive at the hospital about an hour before the scheduled time of the procedure. Your physician will tell you whether to take your regular medications during the fasting period and may give you other special instructions.
    [Show full text]
  • Ultrasound-Guided Percutaneous Core Needle Biopsy of Abdominal
    Original Article | Experimental and Others Pictorial Essay | Gastrointestinal Imaging https://doi.org/10.3348/kjr.2017.18.2.309 pISSN 1229-6929 · eISSN 2005-8330 Korean J Radiol 2017;18(2):309-322 Ultrasound-Guided Percutaneous Core Needle Biopsy of Abdominal Viscera: Tips to Ensure Safe and Effective Biopsy Jin Woong Kim, MD1, Sang Soo Shin, MD1, 2 1Department of Radiology, 2Center for Aging and Geriatrics, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju 61469, Korea Ultrasound-guided percutaneous core needle biopsy (USPCB) is used extensively in daily clinical practice for the pathologic confirmation of both focal and diffuse diseases of the abdominal viscera. As a guidance tool, US has a number of clear advantages over computerized tomography or magnetic resonance imaging: fewer false-negative biopsies, lack of ionizing radiation, portability, relatively short procedure time, real-time intra-procedural visualization of the biopsy needle, ability to guide the procedure in almost any anatomic plane, and relatively lower cost. Notably, USPCB is widely used to retrieve tissue specimens in cases of hepatic lesions. However, general radiologists, particularly beginners, find USPCB difficult to perform in abdominal organs other than the liver; indeed, a full understanding of the entire USPCB process and specific considerations for specific abdominal organs is necessary to safely obtain adequate specimens. In this review, we discuss some points and techniques that need to be borne in mind to increase the chances of successful USPCB. We believe that the tips and considerations presented in this review will help radiologists perform USPCB to successfully retrieve target tissue from different organs with minimal complications.
    [Show full text]
  • Dysphagia to Liver Failure Vincent Ting Fung Cheung,1 Jey Singanayagam,2 Angus Molyneux,3 Neil Rajoriya1
    Images in… BMJ Case Reports: first published as 10.1136/bcr-2015-212522 on 26 November 2015. Downloaded from Dysphagia to liver failure Vincent Ting Fung Cheung,1 Jey Singanayagam,2 Angus Molyneux,3 Neil Rajoriya1 1Department of DESCRIPTION Gastroenterology, Milton A 54-year-old man presenting with dysphagia, Keynes University Hospital, Milton Keynes, UK weight loss, epigastric pain and cervical lymphaden- 2Department of Radiology, opathy was referred directly to endoscopy. The Milton Keynes University medical history included hypertension and hyper- Hospital, Milton Keynes, UK 3 cholesterolaemia. Blood tests showed normal biliru- Department of bin, aspartate transaminase (AST) 490 iu/L, Histopathology, Milton Keynes γ University Hospital, Milton -glutamyl transferase (GGT) 535 iu/L, alkaline Keynes, UK phosphatase (ALP) 829 iu/L and prothrombin time (PT) 13 s. Correspondence to Gastroscopy showed a lower oesophageal lesion Dr Vincent Ting Fung Cheung, fi [email protected] ( gure 1) with biopsies showing high-grade dyspla- sia. A CT scan showed lower oesophageal wall Accepted 19 September 2015 thickening and multiple lymphadenopathy in the chest/abdomen but no liver metastases (figure 2). The local multidisciplinary team meeting outcome was for repeat oesophageal biopsies and supraclavi- cular lymph node biopsy to exclude a lymphoma. The patient thereafter clinically deteriorated over Figure 2 CT scan showing oesophageal cancer (red a 4-week period, developing jaundice. On admis- arrow) but no obvious liver lesions. sion, he became overtly encephalopathic within 48 h, with a suggestion of acute liver failure. Bloods revealed: bilirubin 238 μmol/L, AST 1034 iu/L, GGT 569 iu/L, ALP 887 iu/L, albumin 20 g/L, PT 27.2 s and lactate 4.7 mmol/L.
    [Show full text]
  • Malignant Ascites Ascites Fluid Analysis: Mandatory Tests
    Approach to Ascites Paul Martin MD, FRCP,FRCPI Division of Hepatology, University of Miami. • 62 year old man referred with abdominal distension. • Remote icteric illness during college • Describes himself as social drinker • P/E mild muscle wasting, BP 110/70, Pulse 90/minute, afebrile • Mild flank distension, diminished liver span with splenic dullness ? Shifting dullness, no fluid wave • Initial Labs: Bilirubin 1.9 mgs/dl, AST 70, ALT 23, alk phos 135, platelet count 110 k, INR 1.2 • Ultrasound perfomed ULTRASOUND IS THE MOST SENSITIVE METHOD TO DETECT ASCITES Ultrasound is the Most Sensitive Method to Detect Ascites Ascites Liver Ascites Initial workup DIAGNOSTIC PARACENTESIS Diagnostic Paracentesis Indications New-onset ascites Admission to hospital Symptoms/signs of SBP Renal dysfunction Unexplained encephalopathy Contraindication s None INITIAL WORKUP OF ASCITES: DIAGNOSIS PARACENTESIS Initial Workup of Ascites Diagnostic Paracentesis Optional Glucose, LDH Amylase Protein/Albumin Routine ? secondary ? infection cirrhotic ? pancreatic ascites PMN count ascites Cytology Culture ? SBP ? malignant ascites Ascites Fluid Analysis: Mandatory Tests • Cell count – WBC & RBC – Purple top tube • Serum albumin - ascites albumin gradient (SAAG) – Terms exudate & transudate – Should no longer be used – Apply to only pleural effusions • Cultures – 10-20 ml in blood culture bottles ASCITES CAN BE CHARACTERIZED BY SERUM-ASCITES ALBUMIN GRADIENT (SAAG) AND ASCITES PROTEIN Ascites Can Be Characterized by Serum- Ascites Albumin Gradient (SAAG)
    [Show full text]
  • 5. Guidelines for the Management of Malignant Ascites in Palliative Care
    5. GUIDELINES FOR THE MANAGEMENT OF MALIGNANT ASCITES IN PALLIATIVE CARE 5.1 GENERAL PRINCIPLES Ascites is the accumulation of fluid in the peritoneal cavity. 1, 2 Malignancy is the underlying cause in approximately 10% of all cases of ascites. About 15- 50% of patients with malignancy will develop ascites. 3 Cancers commonly associated with the development of ascites include breast, colorectal, endometrial, gastric, ovarian and pancreatic. 3 Non-malignant causes of ascites include liver disease, congestive cardiac failure, nephrotic syndrome, pancreatitis, tuberculosis and bowel perforation. 2, 3 Several different pathophysiological mechanisms are implicated in the development of malignant ascites. These include: 4 − peritoneal lymphatic obstruction. − hypoalbuminaemia leading to a reduction in oncotic pressure. − increased capillary permeability. − increased portal vein pressure with activation of the renin-angiotensin pathway. Symptoms resulting from an accumulation of ascitic fluid include abdominal bloating / swelling, pain, nausea and vomiting, anorexia, fatigue, peripheral oedema, heartburn and dyspnoea. 5 Malignant ascites carries a poor prognosis. Management should be aimed at maximising patient comfort and quality of life. 7 Management options for malignant ascites include diuretic therapy, therapeutic paracentesis and peritoneovenous shunts. 8 Oncological interventions may be helpful in ovarian carcinoma and lymphoma. Hormonal therapy may be useful in hormone sensitive malignancies such as some breast cancers. 2, 7 9 There is no evidence that any particular therapeutic option is more effective than another. 5.2 GUIDELINES 5.2.1 Diuretic therapy Diuretic therapy should be considered in every patient with malignant ascites particularly those with a prognosis of greater than 4 weeks. Urea and electrolytes should be checked before starting treatment and during treatment as appropriate.
    [Show full text]
  • Icd-9-Cm (2010)
    ICD-9-CM (2010) PROCEDURE CODE LONG DESCRIPTION SHORT DESCRIPTION 0001 Therapeutic ultrasound of vessels of head and neck Ther ult head & neck ves 0002 Therapeutic ultrasound of heart Ther ultrasound of heart 0003 Therapeutic ultrasound of peripheral vascular vessels Ther ult peripheral ves 0009 Other therapeutic ultrasound Other therapeutic ultsnd 0010 Implantation of chemotherapeutic agent Implant chemothera agent 0011 Infusion of drotrecogin alfa (activated) Infus drotrecogin alfa 0012 Administration of inhaled nitric oxide Adm inhal nitric oxide 0013 Injection or infusion of nesiritide Inject/infus nesiritide 0014 Injection or infusion of oxazolidinone class of antibiotics Injection oxazolidinone 0015 High-dose infusion interleukin-2 [IL-2] High-dose infusion IL-2 0016 Pressurized treatment of venous bypass graft [conduit] with pharmaceutical substance Pressurized treat graft 0017 Infusion of vasopressor agent Infusion of vasopressor 0018 Infusion of immunosuppressive antibody therapy Infus immunosup antibody 0019 Disruption of blood brain barrier via infusion [BBBD] BBBD via infusion 0021 Intravascular imaging of extracranial cerebral vessels IVUS extracran cereb ves 0022 Intravascular imaging of intrathoracic vessels IVUS intrathoracic ves 0023 Intravascular imaging of peripheral vessels IVUS peripheral vessels 0024 Intravascular imaging of coronary vessels IVUS coronary vessels 0025 Intravascular imaging of renal vessels IVUS renal vessels 0028 Intravascular imaging, other specified vessel(s) Intravascul imaging NEC 0029 Intravascular
    [Show full text]